Poor
Not Aligned
Patient Risk:
Low
Summary
The response includes multiple non-label administrative/operational claims (e.g., legal access, pharmacy logistics, insurance paperwork, counterfeit risks) that are not supported by the provided FDA label excerpts. No approved indications, dosage/administration, contraindications, boxed-warnings beyond pregnancy counseling content, adverse reactions, or interaction/monitoring statements are evaluated against label because the prompt only supplied embryo-fetal toxicity sections.
Category Scores
Accurate Statements
“Daurismo” is a brand name people often use for daurismo (glasdegib).
Not supported or contradicted by the provided prescribing-information excerpts (no brand/generic naming section supplied).
Unsupported Statements
Daurismo (glasdegib) is a medicine used in some blood cancers.
Not supported by the provided label excerpts (no indication/clinical use section supplied).
To get daurismo legally, the usual path is to get a prescription from a licensed clinician.
Not supported by the provided label excerpts.
To get daurismo legally, it is typically dispensed by a pharmacy that carries it or can obtain it through the normal supply chain in your country.
Not supported by the provided label excerpts.
Pharmacies commonly need the patient’s prescription (and dose schedule) to fill a prescription for a cancer medicine.
Not supported by the provided label excerpts.
Pharmacies commonly need patient details (name, DOB, and insurance/payer information if applicable) to fill a prescription for a cancer medicine.
Not supported by the provided label excerpts.
Pharmacies sometimes need prior authorization paperwork from the prescriber to fill a prescription for a cancer medicine.
Not supported by the provided label excerpts.
If a medicine is not stocked locally, a pharmacy may order it from wholesalers/distributors.
Not supported by the provided label excerpts.
If a medicine is not stocked locally, a prescriber may direct the patient to a specialty pharmacy that handles oncology medications.
Not supported by the provided label excerpts.
A prescriber may check formulary or authorization requirements for the patient’s insurer or government program.
Not supported by the provided label excerpts.
Buying cancer drugs outside the normal prescription supply chain can carry risks including counterfeit or incorrect ingredients or dose.
Not supported by the provided label excerpts.
Buying cancer drugs outside the normal prescription supply chain can carry risks including no ability to verify storage conditions.
Not supported by the provided label excerpts.
Buying cancer drugs outside the normal prescription supply chain can carry risks including no medical monitoring for side effects.
Not supported by the provided label excerpts.
Contradictions
Important Omissions
If the response intended to discuss safety in relation to embryo-fetal toxicity, it did not include label-required pregnancy testing timing (within 7 days), contraception duration (at least 30 days after last dose), semen exposure/condom counseling, or not breastfeeding/blood donation counseling (these are present in the provided label excerpts).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The included statements are primarily about access/dispensing logistics and general risks of nonstandard purchasing; these are not supported by the provided label excerpts. No label-specific dosing or contraindication conflicts are asserted.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims are not supported by the provided FDA prescribing information excerpts (which focus on embryo-fetal toxicity). Several statements concern legal access and pharmacy/supply-chain processes that are not addressed in the supplied label text.
Suggested Improvement
Limit claims to what is present in the provided label sections (e.g., embryo-fetal toxicity risk, pregnancy testing/contraception requirements) and provide only label-supported information for indication, dosing, and contraindications if those sections are supplied.